When we treat patient outreach as a high-volume objective with a "blunt instrument" approach, we are essentially shooting in the dark.
As a physician, I’ve learned that the most critical clinical milestone isn't always the treatment itself. It’s the moment a patient decides to seek it.
For those navigating Substance Use Disorder (SUD), this moment is incredibly fragile. These are complex patients dealing with a web of stigma and often several past attempts at recovery. Every patient is on a unique journey: some are ready to seek a program today, while others are still debating if they should ever try again, and some remain in denial. We cannot expect a "one-size-fits-all" approach to work for such a nuanced population. We need to reach people when they’re most receptive to receiving care.
When we treat patient outreach as a high-volume objective with a "blunt instrument" approach, we are essentially shooting in the dark. Hope is not a strategy, especially when it comes to chronic diseases like substance abuse. To truly close gaps in care, we must move away from disconnected data sets and toward a precision-based strategy.
It is about identifying both where a patient is on their journey and, more importantly, precisely when and how they might be receptive to receiving care. Identifying patients early allows us to move past the noise and focus limited clinical resources on the members who need them most.
I have seen the power of this precision outreach firsthand through RadiantGraph’s work. In a program with Pelago, they were able to identify members with specific evidence of risk for Alcohol Use Disorder (AUD). By delivering outreach tailored specifically to that need, rather than generic messaging, the program achieved a 15.8x lift in enrollment within it’s precision audience compared to broad SUD outreach.
Beyond just finding the right patients, precision allows us to be significantly more efficient with clinical resources. In a separate campaign, RadiantGraph utilized their Smart Spend model to rank members by their likelihood to engage. By focusing only on the top 70% of that ranked list, were able to reduce the outreach audience by 30% while still preserving 100% of projected registrations. This methodology isn't limited to a single condition. When applying similar predictive scoring to pharmacist outbound calls for other clinical programs, a 40% reduction in outreach time was seen. It is clear that smarter engagement doesn’t just improve the bottom line—it enables clinicians to be more impactful in every conversation, removing the "guesswork" from their days.
If we can solve the engagement challenge for a condition as complex and stigmatized as substance abuse, we can do it for any clinical program. Whether it’s chronic pain, OCD, or smoking cessation, the goal remains the same, ensuring clinical care resources are focused on the patients who need them most, at the exact moment they are ready to say "yes."
Personally, I’d love to see this precision-based approach applied across all conditions, because no patient fits into a single box. When we stop guessing and start identifying the right moment for connection, we finally start building the trust bridge to care that our patients truly deserve.